Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy

Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy

Background Indoleamine-2,3-dioxygenase 1 (IDO1) has been intensively pursued as a therapeutic target to reverse the immunosuppressive cancer-immune milieu and promote tumor elimination. However, recent failures of phase III clinical trials with IDO1 inhibitors involved in cancer immunotherapies high...

Full description

Saved in:
Bibliographic Details
Main Authors: Lulu Zhang, Yihai Cao, Lin Xie, Ming-Rong Zhang, Kuan Hu, Yanhong Duo, Takashi Shimokawa, Katsushi Kumata, Yiding Zhang, Cuiping Jiang, Nobuki Nengaki, Hidekatsu Wakizaka
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002616.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items